HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis.

Abstract
Early restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) without antecedent thrombolytic therapy in patients with acute myocardial infarction (AMI) was assessed by performing in-hospital cardiac catheterization in 62 (88%) of 70 consecutive patients. Specific attention was focused on the effectiveness of the intracoronary administration of urokinase in cases with angiographic residual thrombus after successful direct PTCA. The following two treatment regimens were used: PTCA alone (43 patients) and PTCA followed by the intracoronary infusion of urokinase (27 patients). The rate of early restenosis was higher after successful direct PTCA alone (28%) than after direct PTCA followed by intracoronary urokinase (5%). Bleeding complications were no different between the two groups. These findings suggest that intracoronary urokinase can be effective in reducing early restenosis in patients with angiographic residual thrombus after successful direct PTCA. Therefore early restenosis may be related to residual intracoronary thrombus.
AuthorsH Morishita, R Hattori, T Aoyama, C Kawai, Y Yui
JournalAmerican heart journal (Am Heart J) Vol. 123 Issue 5 Pg. 1153-6 (May 1992) ISSN: 0002-8703 [Print] United States
PMID1575126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Urokinase-Type Plasminogen Activator
Topics
  • Aged
  • Angioplasty, Balloon, Coronary
  • Cardiac Catheterization
  • Coronary Angiography
  • Coronary Thrombosis (complications, prevention & control, therapy)
  • Coronary Vessels
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (etiology, therapy)
  • Recurrence
  • Retrospective Studies
  • Urokinase-Type Plasminogen Activator (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: